drugset / Trial / NCT03809663
A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This phase 2b study is designed to evaluate the safety and efficacy of tezepelumab as a monotherapy and explore its efficacy as adjunct therapy in subjects with moderate-to-severe atopic dermatitis (AD).
Timeline
- Start
- 2019-03-15
- Primary completion
- 2020-05-12
- Completion
- 2020-12-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tezepelumab | Monoclonal antibody | 210 mg | Subcutaneous |
| Subject | Tezepelumab | Monoclonal antibody | 280 mg | Subcutaneous |
| Subject | Tezepelumab | Monoclonal antibody | 420 mg | Subcutaneous |